Ovid Therapeutics Inc.   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (2014)

Organization Overview

First Clinical Trial
2016
NCT02996305
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Ovid Therapeutics | Ovid Therapeutics Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

gaboxadol (5 trials)

Drugs in Phase 2 Trials (1)

Soticlestat (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angelman Syndrome (Phase 3)

Brain Diseases (Phase 2)

Deficiency Diseases (Phase 2)

Epilepsies, Myoclonic (Phase 2)

Epilepsy (Phase 2)

Fragile X Syndrome (Phase 2)

Lennox Gastaut Syndrome (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 2